The Swedish National Board of Health and Welfare rejects prioritising andrology as a speciality

Male infertility can be linked to a shorter lifespan and several severe diseases, but when couples who want children are examined, the focus is on the woman. Ex...

Webinar: Clinical evaluation and clinical investigation of medical devices

Whether you are a small medtech company or a large one, this webinar is a must-attend for anyone curious about how clinical studies on medical devices are conducted.

Upcoming event: New updates on drugs

At Medicon Valley Alliance venues in Copenhagen/Örestad April 1 2020 the meeting New updates in Drug Formulation & Bioavailability takes place for the for the eighth time.

The Swedish Research Council gets go-ahead for more long-term funding

Following a government decision, the Swedish Research Council will soon be able to approve ten-year grant periods for funding research infrastructure, which may...

Krönika: Collaboration across borders

Founder of Bioarctic, Lars Lannfelt, is honoured: “I want to create something for the future”

It´s like a scientist’s dream: to be the world’s first with a drug that genuinely affects one of our major diseases. Lars Lannfelt and his company Bioarctic hav...

Quality Assurance for the Highest Medical Standards

Metrology Solutions for Medical Components.

“We aim to be a start-up company with an academic spirit”

Chronic pain and Alzheimer’s are two diseases that plague many people worldwide and seem impossible to cure. However, Huddinge-based company Alzecure is working...

Vertex betalar 52 miljarder för bolag inom autoimmuna sjukdomar

Amerikanska Vertex Pharmaceuticals köper biotechbolaget Alpine Immune Sciences för 4,9 miljarder dollar, motsvarande drygt 52 miljarder kronor.

Ingrid Lönnstedt: What does the p-value mean?

The smaller the better, and preferably smaller than 0.05. A p-value smaller than 5% means that the treatment effect is statistically significant at 5% significa...

Don't miss ZEISS Quality Innovation Days

Digital event April 15-19, 2024.

The new ZEISS Celldiscoverer 7 has been launched

Adaptable automation for advanced workflows.

Introducing ZEISS arivis Pro 4.2

Your solution for advanced image analysis and visualization.

Nanexa develops depot formulation of the diabetes and obesity drug Saxenda

Uppsala-based company Nanexa has signed an agreement with a German contract research company to start a clinical study with a monthly depot of liraglutide. The ...

Improved processes and more

Discover the full potential and benefits.

Unexpected study results on testosterone – no reduction in fracture risk

Testosterone treatment is known to increase bone density and bone quality. However, a study now suggests that supplementation with the male sex hormone does not...

The International Vaccine Institute’s office in Sweden is expanding

The International Vaccine Institute’s Stockholm office has been open for over a year. During the past year, training programmes and projects have been launched,...

40,000 DNA extractions daily

It's great when things run quickly: 20 minutes per extraction process and a new plate every 2.5 minutes – the Dutch company Synchron Lab Automation, in cooperat...

“I am driven by the desire to develop a product that can be sold worldwide”

Ranked number one in the world by the WHO in diarrhoea research and soon in phase III studies for its vaccine candidate – Scandinavian Biopharma is rushing forw...

Ossiform: Quality control of 3D printed bone implants

Ossiform chose the GOM Scan 1.

Automate E2E Image Analysis Pipelines

ZEISS arivis Pro - Your End-to-End Scientific Image Analysis Software.

Sweden is organising a large life science conference as part of the EU presidency

On 26-27 June, Sweden will host a European meeting on life science.

Fullt godkännande i EU för Calliditas njurläkemedel – "Viktig händelse"

Calliditas läkemedel Kinpeygo har fått ett fullständigt godkännande från EU-kommissionen för behandling av vuxna med njursjukdomen IgA-nefropati, IgAN.

He is heading a new company for the development of Coegin’s cancer drug

The biotechnology company Coegin Pharma places the development of its drug candidate AVX420 in a newly formed company, Avexxin Oncology, based in Norway, and Jo...